Compare Abeona Therapeutics Inc (ABEO) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Invesco NASDAQ 100 ETF — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Invesco NASDAQ 100 ETF trades at $292.35. Which is the better fit depends on your goals.
| ABEO | QQQM | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $307.23 |
52-Week Low | $4.17 | $227.35 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
QQQM trades at $297.52, up 1.4% with bullish technical signals from moving averages. The ETF benefits from SpaceX's imminent Nasdaq-100 inclusion on July 7, 2026, expected to bring modest 1% weighting. Technical analysis shows support at $296 and resistance at $299, with overall bullish momentum supported by 12 buy signals versus 4 sell signals.
The outlook remains positive with AI-driven growth exposure and new index additions. Risks include concentration in large-cap tech and market volatility. Analyst sentiment favors long-term holding given the ETF's cost efficiency and growth potential in technology sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
